BACKGROUND: Evidence regarding the efficacy or effectiveness of the disease-modifying drugs (DMDs) in the older multiple sclerosis (MS) population is scarce. This has contributed to a lack of evidence-based treatment recommendations for the ageing MS population in practice guidelines. We examined the relationship between age (<55 and ≥55 years), DMD exposure and health service use in the MS population. METHODS: We conducted a population-based observational study using linked administrative health data from British Columbia, Canada. We selected all persons with MS and followed from the most recent of their first MS or demyelinating event, 18th birthday or 01-January-1996 (index date) until the earliest of emigration, death or 31-December-2017 (study end). We assessed DMD exposure status over time, initially as any versus no DMD, then by generation (first or second) and finally by each individual DMD. Age-specific analyses were conducted with all-cause hospitalizations and number of physician visits assessed using proportional means model and negative binomial regression with generalized estimating equations. RESULTS: We included 19,360 persons with MS (72% were women); 10,741/19,360 (56%) had ever reached their 55th birthday. Person-years of follow-up whilst aged <55 was 132,283, and 93,594 whilst aged ≥55. Any DMD, versus no DMD in the <55-year-olds was associated with a 23% lower hazard of hospitalization (adjusted hazard ratio, aHR0.77; 95%CI 0.72-0.82), but not in the ≥55-year-olds (aHR0.95; 95%CI 0.87-1.04). Similar patterns were observed for the first and second generation DMDs. Exposure to any (versus no) DMD was not associated with rates of physician visits in either age group (<55 years: adjusted rate ratio, aRR1.02; 95%CI 1.00-1.04 and ≥55 years: aRR1.00; 95%CI 0.96-1.03), but variation in aRR was observed across the individual DMDs. CONCLUSION: Our study showed beneficial effects of the DMDs used to treat MS on hospitalizations for those aged <55 at the time of exposure. In contrast, for individuals ≥55 years of age exposed to a DMD, the hazard of hospitalization was not significantly lowered. Our study contributes to the broader understanding of the potential benefits and risks of DMD use in the ageing MS population.

Brain and Mind Centre University of Sydney Sydney NSW Australia

College of Pharmacy and Nutrition University of Saskatchewan Saskatoon SK Canada

Department of Community Health Sciences Max Rady College of Medicine Rady Faculty of Health Sciences University of Manitoba Winnipeg MB Canada

Department of Internal Medicine Max Rady College of Medicine Rady Faculty of Health Sciences University of Manitoba Winnipeg MB Canada

Department of Medicine Division of Neurology and the Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada

Department of Neurology Medical Faculty University Hospital Heinrich Heine University Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University in Olomouc Olomouc Czechia

Nova Scotia Health Authority and the Departments of Psychiatry Psychology and Neuroscience and Medicine Dalhousie University Halifax NS Canada

Research Department of Primary Care and Population Health University College London London United Kingdom

See more in PubMed

Awad A, Stüve O. Multiple Sclerosis in the Elderly Patient. Drugs Aging (2010) 27:283–94. doi: 10.2165/11532120-000000000-00000 PubMed DOI

Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, et al. . Epidemiology and Treatment of Multiple Sclerosis in Elderly Populations. Nat Rev Neurol (2019) 15:329–42. doi: 10.1038/s41582-019-0183-3 PubMed DOI

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. . Comprehensive Systematic Review Summary: Disease-Modifying Therapies for Adults With Multiple Sclerosis. Neurology (2018) 90:789–800. doi: 10.1212/WNL.0000000000005345 PubMed DOI

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. . Practice Guideline Recommendations Summary: Disease-Modifying Therapies for Adults With Multiple Sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology (2018) 90:777–88. doi: 10.1212/WNL.0000000000005347 PubMed DOI

Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-Analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front Neurol (2017) 8:577. doi: 10.3389/fneur.2017.00577 PubMed DOI PMC

Prosperini L, Haggiag S, Tortorella C, Galgani S, Gasperini C. Age-Related Adverse Events of Disease-Modifying Treatments for Multiple Sclerosis: A Meta-Regression. Mult Scler (2021) 27:1391–402. doi: 10.1177/1352458520964778 PubMed DOI

Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, et al. . First-Line Therapies in Late-Onset Multiple Sclerosis: An Italian Registry Study. Eur J Neurol (2021) 28:4117–23. doi: 10.1111/ene.15006 PubMed DOI PMC

D’Amico E, Patti F, Zanghì A, Chisari CG, Lo Fermo S, Zappia M. Late-Onset and Young-Onset Relapsing-Remitting Multiple Sclerosis: Evidence From a Retrospective Long-Term Follow-Up Study. Eur J Neurol (2018) 25:1425–31. doi: 10.1111/ene.13745 PubMed DOI

Nicholas J, Boster A, Wu N, Yeh W-S, Fay M, Kendter J, et al. . Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates From US Insurance Claims Data. Pharmacoecon Open (2018) 2:31–41. doi: 10.1007/s41669-017-0035-2 PubMed DOI PMC

Al-Sakran L, Marrie RA, Blackburn D, Knox K, Evans C. Association Between Disease-Modifying Therapies for Multiple Sclerosis and Healthcare Utilisation on a Population Level: A Retrospective Cohort Study. BMJ Open (2019) 9:e033599. doi: 10.1136/bmjopen-2019-033599 PubMed DOI PMC

Pirttisalo AL, Sipilä JOT, Soilu-Hänninen M, Rautava P, Kytö V. Adult Hospital Admissions Associated With Multiple Sclerosis in Finland in 2004-2014. Ann Med (2018) 50:354–60. doi: 10.1080/07853890.2018.1461919 PubMed DOI

Sanchirico M, Caldwell-Tarr A, Mudumby P, Hashemi L, Dufour R. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients With Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment. Neurol Ther (2019) 8:121–33. doi: 10.1007/s40120-018-0123-y PubMed DOI PMC

Simbrich A, Thibaut J, Khil L, Berger K, Riedel O, Schmedt N. Drug-Use Patterns and Severe Adverse Events With Disease-Modifying Drugs in Patients With Multiple Sclerosis: A Cohort Study Based on German Claims Data. Neuropsychiatr Dis Treat (2019) 15:1439–57. doi: 10.2147/ndt.S200930 PubMed DOI PMC

Statistics Canada. Census Profile, 2016 Census (2017). Available at: https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E (Accessed 1 February, 2021).

British Columbia Ministry of Health . Consolidation File (MSP Registration & Premium Billing). V2. Population Data BC [Publisher]. Data Extract. MOH (2017). Available at: http://www.popdata.bc.ca/data.

BC Vital Statistics Agency . Vital Statistics Deaths. V2. Population Data BC [publisher]. Data Extract. BC Vital Statistics Agency; (2017). Available at: http://www.popdata.bc.ca/data.

British Columbia Ministry of Health . Medical Services Plan (MSP) Payment Information File. V2. Population Data BC [publisher]. Data Extract. MOH; (2017). Available at: http://www.popdata.bc.ca/data.

Canadian Institute for Health Information . Discharge Abstract Database (Hospital Separations). V2 (2017). Population Data BC [publisher]. Data Extract. MOH. Available at: http://www.popdata.bc.ca/data (Accessed (2017)).

BC Ministry of Health . PharmaNet. V2. BC Ministry of Health [Publisher]. Data Extract. Data Stewardship Committee (2017). Available at: http://www.popdata.bc.ca/data.

Kingwell E, Zhu F, Marrie RA, Fisk JD, Wolfson C, Warren S, et al. . High Incidence and Increasing Prevalence of Multiple Sclerosis in British Columbia, Canada: Findings From Over Two Decades (1991–2010). J Neurol (2015) 262:2352–63. doi: 10.1007/s00415-015-7842-0 PubMed DOI PMC

Marrie RA, Yu N, Blanchard J, Leung S, Elliott L. The Rising Prevalence and Changing Age Distribution of Multiple Sclerosis in Manitoba. Neurology (2010) 74:465–71. doi: 10.1212/WNL.0b013e3181cf6ec0 PubMed DOI

Ng HS, Zhu F, Kingwell E, Zhao Y, Yao S, Ekuma O, et al. . Characteristics of a Population-Based Multiple Sclerosis Cohort Treated With Disease-Modifying Drugs in a Universal Healthcare Setting. Expert Rev Neurother (2020) 21:131–40. doi: 10.1080/14737175.2021.1847085 PubMed DOI

Canadian Institute for Health Information and Statistics Canada . Health Indicators 2013 (2013). Available at: https://www.cihi.ca/sites/default/files/document/health-indicators-2013-en.pdf (Accessed 3 March, 2021).

Deyo RA, Cherkin DC, Ciol MA. Adapting a Clinical Comorbidity Index for Use With ICD-9-CM Administrative Databases. J Clin Epidemiol (1992) 45:613–9. doi: 10.1016/0895-4356(92)90133-8 PubMed DOI

Marrie RA, Bernstein CN, Peschken CA, Hitchon CA, Chen H, Fransoo R, et al. . Intensive Care Unit Admission in Multiple Sclerosis: Increased Incidence and Increased Mortality. Neurology (2014) 82:2112–9. doi: 10.1212/WNL.0000000000000495 PubMed DOI PMC

Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. . Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs. JAMA (2004) 292:2585–90. doi: 10.1001/jama.292.21.2585 PubMed DOI

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. . The Prevalence of MS in the United States: A Population-Based Estimate Using Health Claims Data. Neurology (2019) 92:e1029–40. doi: 10.1212/WNL.0000000000007035 PubMed DOI PMC

Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, et al. . Association Between Beta-Interferon Exposure and Hospital Events in Multiple Sclerosis. Pharmacoepidemiol Drug Saf (2014) 23:1213–22. doi: 10.1002/pds.3667 PubMed DOI

Ng HS, Zhu F, Kingwell E, Zhao Y, Yao S, Ekuma O, et al. . Disease-Modifying Drugs for Multiple Sclerosis and Subsequent Health Service Use. Mult Scler (2021) 13524585211063403:1–14. doi: 10.1177/13524585211063403 PubMed DOI PMC

Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric Regression for the Mean and Rate Functions of Recurrent Events. J R Stat Soc Ser B Stat Methodol (2000) 62:711–30. doi: 10.1111/1467-9868.00259 DOI

Ballinger GA. Using Generalized Estimating Equations for Longitudinal Data Analysis. Organ Res Methods (2004) 7:127–50. doi: 10.1177/1094428104263672 DOI

Cisternas M, Bartolome L, Gitar B, Hulbert E, Trenz H, Patel V, et al. . Health Care Resource Utilization and Disease Modifying Treatment Use in Multiple Sclerosis Patients by Age and Insurance Type. Curr Med Res Opin (2021) 37:597–604. doi: 10.1080/03007995.2021.1885367 PubMed DOI

Zhang Y, Gonzalez Caldito N, Shirani A, Salter A, Cutter G, Culpepper W, et al. . 2ndAging and Efficacy of Disease-Modifying Therapies in Multiple Sclerosis: A Meta-Analysis of Clinical Trials. Ther Adv Neurol Disord (2020) 13:1756286420969016. doi: 10.1177/1756286420969016 PubMed DOI PMC

Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and Immunosuppressants for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis. Cochrane Database Syst Rev (2015) 9:CD011381. doi: 10.1002/14651858.CD011381.pub2 PubMed DOI PMC

Bonafede MM, Johnson BH, Watson C. Health Care-Resource Utilization Before and After Natalizumab Initiation in Multiple Sclerosis Patients in the US. Clinicoecon Outcomes Res (2013) 6:11–20. doi: 10.2147/CEOR.S55779 PubMed DOI PMC

O’Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, et al. . Teriflunomide Reduces Relapse-Related Neurological Sequelae, Hospitalizations and Steroid Use. J Neurol (2013) 260:2472–80. doi: 10.1007/s00415-013-6979-y PubMed DOI PMC

Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, et al. . Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies. Clin Ther (2015) 37:2543–51. doi: 10.1016/j.clinthera.2015.09.011 PubMed DOI

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, et al. . Additional Efficacy Endpoints From Pivotal Natalizumab Trials in Relapsing-Remitting MS. J Neurol (2012) 259:898–905. doi: 10.1007/s00415-011-6275-7 PubMed DOI

Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New Perspectives in the Natural History of Multiple Sclerosis. Neurology (2010) 74:2004–15. doi: 10.1212/WNL.0b013e3181e3973f PubMed DOI

Tremlett H, Zhao Y, Joseph J, Devonshire V. Relapses in Multiple Sclerosis Are Age- and Time-Dependent. J Neurol Neurosurg Psychiatry (2008) 79:1368–74. doi: 10.1136/jnnp.2008.145805 PubMed DOI

Ziemssen T, Rauer S, Stadelmann C, Henze T, Koehler J, Penner IK, et al. . Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. PloS One (2015) 10:e0138243. doi: 10.1371/journal.pone.0138243 PubMed DOI PMC

Baldassari LE, Fox RJ. Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs (2018) 78:1549–66. doi: 10.1007/s40265-018-0984-5 PubMed DOI

Faissner S, Plemel JR, Gold R, Yong VW. Progressive Multiple Sclerosis: From Pathophysiology to Therapeutic Strategies. Nat Rev Drug Discov (2019) 18:905–22. doi: 10.1038/s41573-019-0035-2 PubMed DOI

Shirani A, Zhao Y, Petkau J, Gustafson P, Karim ME, Evans C, et al. . Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment. BioMed Res Int (2015) 451912:1–11. doi: 10.1155/2015/451912 PubMed DOI PMC

Sanofi Genzyme A Division of Sanofi-Aventis Canada Inc. LEMTRADA (Alemtuzumab 12mg/1.2ml) Product Monograph [Online] (2020). Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html (Accessed 11 January, 2021).

Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, et al. . Requirement for Safety Monitoring for Approved Multiple Sclerosis Therapies: An Overview. Clin Exp Immunol (2014) 175:397–407. doi: 10.1111/cei.12206 PubMed DOI PMC

Teva Canada Limited . COPAXONE (Glatiramer Acetate Injection 20mg/1ml and 40mg/1ml) Product Monograph [Online] (2018). Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html (Accessed August 16, 2021).

Novartis Pharmaceuticals Canada Inc . GILENYA (Fingolimod Capsules 0.25mg and 0.5 Mg) Product Monograph [Online] (2019). Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html (Accessed August 16, 2021).

U.S National Library of Medicine ClinicalTrials.gov . Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) (DISCOMS) (2021). Available at: https://clinicaltrials.gov/ct2/show/NCT03073603.

Zhang Y, Salter A, Jin S, Culpepper WJ, 2nd, Cutter GR, Wallin M, et al. . Disease-Modifying Therapy Prescription Patterns in People With Multiple Sclerosis by Age. Ther Adv Neurol Disord (2021) 14:1–7. doi: 10.1177/17562864211006499 PubMed DOI PMC

Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Tennakoon A, et al. . Dramatically Changing Rates and Reasons for Hospitalization in Multiple Sclerosis. Neurology (2014) 83:929–37. doi: 10.1212/WNL.0000000000000753 PubMed DOI PMC

Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review